Yes. Given the NoPain Act, BIEL’s more focused emphasis on RecoveryRx, and the possibility of insurance reimbursement, I believe these collectively propel the value of the patents. The NoPain Act and its potential for BIEL and a buyer or merger/partner is the wildcard right now.
A merger with a power house would be the most favorable outcome for shareholders given the partner’s ability to conduct more robust validity within timely clinical trials that would lend more favorably for inclusion of RRx under the Act, thus wider adoption by healthcare. Equally important, they could further the process of insurance reimbursement given their financial agility, having established networks/liaisons, and most importantly, their lobbying power, all the while having the resources to meet any product demand and whatnot.
However, I would think one would want the whole enchilada, and so a buyout is more likely. Not as advantageous for the shareholder given the low PPS negotiation point, but certainly more advantageous and less messy for the prospective buyer vs a partner.
When considering BIEL’s patents, they have much more intrinsic value at this point given the Act and it’s potential for RRx insurance reimbursement, and again…the very low PPS starting negotiation point is quite advantageous for the prospective buyer. Overall, a buyer would have the financial means to structure a satisfactory outcome for BIEL management even with having to consider IBEX and St. John’s. But likely not as favorable for common shareholders vs a merger.
All imo.
News 
Market Data 
Discover 
AI
